| 2. |
- Gotzsche, Casper R., et al.
(författare)
-
Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures
- 2012
-
Ingår i: Neurobiology of Disease. - : Elsevier BV. - 0969-9961. ; 45:1, s. 288-296
-
Tidskriftsartikel (refereegranskat)abstract
- We recently demonstrated that recombinant adeno-associated viral vector-induced hippocampal overexpression of neuropeptide Y receptor, Y2, exerts a seizure-suppressant effect in kindling and kainate-induced models of epilepsy in rats. Interestingly, additional overexpression of neuropeptide Y in the hippocampus strengthened the seizure-suppressant effect of transgene Y2 receptors. Here we show for the first time that another neuropeptide Y receptor, Y5, can also be overexpressed in the hippocampus. However, unlike Y2 receptor overexpression, transgene Y5 receptors in the hippocampus had no effect on kainate-induced motor seizures in rats. However, combined overexpression of Y5 receptors and neuropeptide Y exerted prominent suppression of seizures. This seizure-suppressant effect of combination gene therapy with Y5 receptors and neuropeptide Y was significantly stronger as compared to neuropeptide Y overexpression alone. These results suggest that overexpression of Y5 receptors in combination with neuropeptide Y could be an alternative approach for more effective suppression of hippocampal seizures. (C) 2011 Elsevier Inc. All rights reserved.
|
|
| 3. |
- Moller, JE, et al.
(författare)
-
Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction : Results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy
- 2004
-
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 147:3, s. 494-501
-
Tidskriftsartikel (refereegranskat)abstract
- Background Angiotensin-converting enzyme inhibitors have been shown to attenuate adverse remodeling after acute myocardial infarction (AMI), and the same has been suggested for angiotensin 11 type I receptor antagonists in animal models. Therefore the aim of the study was to compare the effects of losartan and captopril on regional systolic, diastolic, and overall left ventricular (LV) function after AMI. Methods Two hundred twenty-five patients aged 50 years with documented AMI and heart failure and/or LV dysfunction were randomly assigned treatment with either losartan (50 mg/d) or captopril (50 mg 3 times/d). Echocardiography was performed at randomization and after 3 months, echocardiograms were analyzed blinded at the core laboratory. Main outcome measures were changes in wall motion score index (WMSI), E-wave deceleration time (E-DT), and Tei index of overall LV function. Results WMSI decreased in both groups (losartan 1.58 +/- 0.23 to 1.52 +/- 0.26, P = .009, captopril 1.60 +/- 0.24 to 1.48 +/- 0.22, P < .001), although the decrease was greater in patients allocated to captopril (captopril -0.12 &PLUSMN, 0.17 vs losartan -0.05 &PLUSMN, 0.19, P = .007). In both groups E-DT increased, although the increase was significant only in patients treated with captoril (193 &PLUSMN, 61 ms to 208 &PLUSMN, 70 ms, P = .05). The change in E-DT was not different between treatment groups (captopril 14 &PLUSMN, 74 ms vs losartan 7 &PLUSMN, 80 ms, P = .52). Tei index decreased in both groups (losartan 0.59 &PLUSMN, 0.13 to 0.55 &PLUSMN, 0.15, P = .04, captopril 0.62 &PLUSMN, 0.15 to 0.55 &PLUSMN, 0.13, P < .001). However, the reduction was significantly greater in patients treated with captopril (captopril -0.08 +/- 0.14 vs losartan -0.03 +/- 0.14, P = .01). Conclusion Losartan and captopril improve systolic and overall IV function after AMI, but the benefit is greater for patients treated with captopril.
|
|
